Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062

Core Insights - Basilea Pharmaceutica Ltd has received an additional USD 25 million from BARDA to advance the development of its antifungal drugs fosmanogepix and BAL2062, following a milestone achievement in a phase 3 study [1][2] - The total potential funding from BARDA could reach approximately USD 268 million over a period of up to 12 years, contingent on successful completion of predefined milestones [2][3] Company Overview - Basilea is a commercial-stage biopharmaceutical company focused on developing innovative treatments for severe bacterial and fungal infections, with two hospital brands already launched: Cresemba and Zevtera [8] - The company has a portfolio that includes preclinical and clinical anti-infective assets, and it is listed on the SIX Swiss Exchange [8] Product Development - Fosmanogepix is a clinical-stage broad-spectrum antifungal with a novel mechanism of action, effective against common and multi-drug-resistant strains of Candida and Aspergillus [3] - BAL2062 is a first-in-class antifungal derived from a natural product, showing fungicidal activity against important molds, including azole-resistant strains [4] Market Need - There is a high medical need for new antifungal treatments due to the life-threatening nature of invasive fungal infections, particularly among immunocompromised patients [5][7] - Invasive candidiasis is a significant nosocomial infection, with Candida species being a leading cause of bloodstream infections in hospitals, and a reported mortality rate as high as 40% [7]